J.p. Marvel Investment Advisors Lowers stake in Pfizer (PFE)

Pfizer (PFE) : J.p. Marvel Investment Advisors reduced its stake in Pfizer by 0.16% during the most recent quarter end. The investment management company now holds a total of 277,397 shares of Pfizer which is valued at $9.6 Million after selling 444 shares in Pfizer , the firm said in a disclosure report filed with the SEC on May 26, 2016.Pfizer makes up approximately 3.30% of J.p. Marvel Investment Advisors’s portfolio.

Other Hedge Funds, Including , Bangor Savings Bank boosted its stake in PFE in the latest quarter, The investment management firm added 586 additional shares and now holds a total of 26,474 shares of Pfizer which is valued at $916,265. Pfizer makes up approx 0.23% of Bangor Savings Bank’s portfolio.Budros Ruhlin Roe reduced its stake in PFE by selling 1,113 shares or 1.48% in the most recent quarter. The Hedge Fund company now holds 74,273 shares of PFE which is valued at $2.5 Million. Pfizer makes up approx 0.87% of Budros Ruhlin Roe’s portfolio.Diamond Hill Capital Management Inc boosted its stake in PFE in the latest quarter, The investment management firm added 524,230 additional shares and now holds a total of 11,245,591 shares of Pfizer which is valued at $373.2 Million. Pfizer makes up approx 2.40% of Diamond Hill Capital Management Inc’s portfolio.Fukoku Mutual Life Insurance Co boosted its stake in PFE in the latest quarter, The investment management firm added 800 additional shares and now holds a total of 278,254 shares of Pfizer which is valued at $9.2 Million. Pfizer makes up approx 2.00% of Fukoku Mutual Life Insurance Co’s portfolio.Amalgamated Bank boosted its stake in PFE in the latest quarter, The investment management firm added 57,619 additional shares and now holds a total of 219,510 shares of Pfizer which is valued at $7.3 Million. Pfizer makes up approx 0.72% of Amalgamated Bank’s portfolio.

Pfizer opened for trading at $34.65 and hit $34.935 on the upside on Wednesday, eventually ending the session at $34.75, with a gain of 0.14% or 0.05 points. The heightened volatility saw the trading volume jump to 2,31,13,119 shares. Company has a market cap of $210,754 M.

On the company’s financial health, Pfizer reported $0.67 EPS for the quarter, beating the analyst consensus estimate by $ 0.12 according to the earnings call on May 3, 2016. Analyst had a consensus of $0.55. The company had revenue of $13005.00 million for the quarter, compared to analysts expectations of $12008.32 million. The company’s revenue was up 19.3% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.51 EPS.

Many Wall Street Analysts have commented on Pfizer. Berenberg Initiated Pfizer on May 12, 2016 to “Hold”, Price Target of the shares are set at $38.Company shares were Reiterated by UBS on May 4, 2016 to “Buy”, Firm has raised the Price Target to $ 38 from a previous price target of $36 .Goldman Resumed Pfizer on Apr 18, 2016 to “Neutral”, Price Target of the shares are set at $35.

Pfizer Inc. is a global biopharmaceutical company. The Company is engaged in discovering developing and manufacturing of healthcare products. Its products include Lyrica the Prevnar family of products Enbrel Celebrex Lipitor Viagra Zyvox Sutent EpiPen Toviaz Tygacil Rapamune Xalkori Inlyta Norvasc BeneFIX Genotropin and Enbrel among others. It operates in three segments: Global Innovative Pharmaceutical segment (GIP) Global Vaccines Oncology and Consumer Healthcare segment (VOC) and Global Established Pharmaceutical segment (GEP). GIP is focused on developing registering and commercializing medications in therapeutic areas such as inflammation cardiovascular/metabolic neuroscience and pain rare diseases and women’s/men’s health. VOC focuses on the development and commercialization of vaccines and products for oncology and consumer healthcare. GEP includes its sterile injectable products and bio similar development portfolio. Its subsidiary is Hospira Inc.

Leave a Reply

Pfizer - Is it time to Sell?

Top Brokerage Firms are advising their investors on Pfizer. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.